Pds Biotechnology Corp (PDSB)

$1.08 +0.04 (3.85%)
Market Cap 49.03M
Revenue (ttm) 0.00
Net Income (ttm) -37.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.48
Volume 131,500
Avg Vol 733,200
Day's Range N/A - N/A
Shares Out 45.40M
Stochastic %K 72%
Beta 1.50
Analysts Strong Sell
Price Target $8.17

Latest News on PDSB

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 3 days ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 8, 2025, 8:00 AM EDT - 11 days ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:35 AM EDT - 23 days ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 27, 2025, 7:30 AM EDT - 23 days ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 25, 2025, 8:00 AM EDT - 25 days ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 18, 2025, 8:00 AM EDT - 4 weeks ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 13, 2025, 8:00 AM EDT - 5 weeks ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

PDS Biotech Leadership to Participate in March Conferences

Mar 11, 2025, 8:00 AM EDT - 5 weeks ago

PDS Biotech Leadership to Participate in March Conferences

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Mar 7, 2025, 8:45 AM EST - 6 weeks ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 27, 2025, 8:00 AM EST - 7 weeks ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 26, 2025, 8:00 AM EST - 7 weeks ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 24, 2025, 8:00 AM EST - 7 weeks ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Feb 20, 2025, 8:00 AM EST - 2 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 8:00 AM EST - 4 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Dec 3, 2024, 8:00 AM EST - 4 months ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 11:18 AM EST - 5 months ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Nov 6, 2024, 8:00 AM EST - 5 months ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Oct 2, 2024, 8:00 AM EDT - 7 months ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology: Continuing The Holding Pattern

Sep 23, 2024, 10:39 AM EDT - 7 months ago

PDS Biotechnology: Continuing The Holding Pattern

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 9, 2024, 8:00 AM EDT - 7 months ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 8 months ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 7, 2024, 8:00 AM EDT - 9 months ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 2, 2024, 9:12 AM EDT - 9 months ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Aug 1, 2024, 7:45 AM EDT - 9 months ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

Jul 31, 2024, 4:01 PM EDT - 9 months ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 9, 2024, 5:46 PM EDT - 1 year ago

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PDS Biotechnology Announces Details of Virtual KOL Event

May 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Details of Virtual KOL Event

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 12:17 PM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Mar 27, 2024, 7:30 AM EDT - 1 year ago

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Mar 20, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Mar 13, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

Jan 26, 2024, 6:59 PM EST - 1 year ago

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

PDS Biotech Announces Retirement of Lauren V. Wood, M.D.

Jan 22, 2024, 4:45 PM EST - 1 year ago

PDS Biotech Announces Retirement of Lauren V. Wood, M.D.

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Jan 16, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Nov 28, 2023, 7:30 AM EST - 1 year ago

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 12:17 PM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 7:30 AM EST - 1 year ago

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

Nov 9, 2023, 8:00 AM EST - 1 year ago

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

Nov 7, 2023, 8:00 AM EST - 1 year ago

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Oct 23, 2023, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Oct 11, 2023, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

Oct 3, 2023, 7:00 AM EDT - 1 year ago

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Oct 2, 2023, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

PDS Biotech to Present at the LD Micro Main Event XVI

Sep 26, 2023, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at the LD Micro Main Event XVI

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

Sep 25, 2023, 8:00 AM EDT - 1 year ago

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 20, 2023, 4:05 PM EDT - 1 year ago

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference